全文获取类型
收费全文 | 452篇 |
免费 | 8篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 23篇 |
妇产科学 | 5篇 |
基础医学 | 14篇 |
口腔科学 | 2篇 |
临床医学 | 103篇 |
内科学 | 139篇 |
皮肤病学 | 17篇 |
神经病学 | 29篇 |
特种医学 | 2篇 |
外科学 | 51篇 |
综合类 | 7篇 |
一般理论 | 1篇 |
预防医学 | 20篇 |
药学 | 30篇 |
肿瘤学 | 19篇 |
出版年
2024年 | 1篇 |
2022年 | 1篇 |
2021年 | 1篇 |
2020年 | 2篇 |
2019年 | 1篇 |
2016年 | 2篇 |
2015年 | 6篇 |
2014年 | 6篇 |
2013年 | 16篇 |
2012年 | 21篇 |
2011年 | 29篇 |
2010年 | 13篇 |
2009年 | 28篇 |
2008年 | 15篇 |
2007年 | 23篇 |
2006年 | 36篇 |
2005年 | 16篇 |
2004年 | 10篇 |
2003年 | 6篇 |
2002年 | 8篇 |
2001年 | 24篇 |
2000年 | 14篇 |
1999年 | 19篇 |
1998年 | 25篇 |
1997年 | 15篇 |
1996年 | 22篇 |
1995年 | 13篇 |
1994年 | 18篇 |
1993年 | 12篇 |
1992年 | 6篇 |
1991年 | 7篇 |
1990年 | 2篇 |
1989年 | 3篇 |
1988年 | 7篇 |
1987年 | 9篇 |
1986年 | 2篇 |
1985年 | 4篇 |
1984年 | 3篇 |
1983年 | 3篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 2篇 |
1978年 | 3篇 |
1977年 | 1篇 |
1973年 | 1篇 |
1963年 | 2篇 |
1959年 | 2篇 |
排序方式: 共有463条查询结果,搜索用时 15 毫秒
61.
Assessment of differences in linear growth among populations in the WHO Multicentre Growth Reference Study 总被引:2,自引:0,他引:2
WHO MULTICENTRE GROWTH REFERENCE STUDY GROUP & Mercedes de Onis 《Acta paediatrica (Oslo, Norway : 1992)》2006,95(S450):56-65
Aim: To assess differences in length/height among populations in the WHO Multicentre Growth Reference Study (MGRS) and to evaluate the appropriateness of pooling data for the purpose of constructing a single international growth standard. Methods: The MGRS collected growth data and related information from 8440 affluent children from widely differing ethnic backgrounds and cultural settings (Brazil, Ghana, India, Norway, Oman and the USA). Eligibility criteria included breastfeeding, no maternal smoking and environments supportive of unconstrained growth. The study combined longitudinal (birth to 24 mo) and cross-sectional (18–71 mo) components. For the longitudinal component, mother–infant pairs were enrolled at delivery and visited 21 times over the next 2 y. Rigorous methods of data collection and standardized procedures were applied across study sites. We evaluate the total variability of length attributable to sites and individuals, differences in length/height among sites, and the impact of excluding single sites on the percentiles of the remaining pooled sample. Results: Proportions of total variability attributable to sites and individuals within sites were 3% and 70%, respectively. Differences in length and height ranged from −0.33 to +0.49 and −0.41 to +0.46 standard deviation units (SDs), respectively, most values being below 0.2 SDs. Differences in length on exclusion of single sites ranged from −0.10 to +0.07, −0.07 to +0.13, and −0.25 to +0.09 SDs, for the 50th, 3rd and 97th percentiles, respectively. Corresponding values for height ranged from −0.09 to +0.08, −0.12 to +0.13, and −0.15 to +0.07 SDs.
Conclusion: The striking similarity in linear growth among children in the six sites justifies pooling the data and constructing a single international standard from birth to 5 y of age. 相似文献
Conclusion: The striking similarity in linear growth among children in the six sites justifies pooling the data and constructing a single international standard from birth to 5 y of age. 相似文献
62.
63.
64.
Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole 总被引:6,自引:6,他引:0
A. S. MEE & J. L. ROWLEY THE LANSOPRAZOLE CLINICAL RESEARCH GROUP 《Alimentary pharmacology & therapeutics》1996,10(5):757-763
Background: Lansoprazole, a substituted benzimidazole, is a proton pump inhibitor which is highly effective in the control of 24-h intragastric acidity. The aim of this multicentre, randomized, double-blind study was to compare lansoprazole 30 mg once daily and omeprazole 20 mg once daily in the symptom relief and healing of patients with reflux oesophagitis. Methods: Six hundred and four patients with endoscopically proven oesophagitis and a recent history of heartburn were randomly assigned to receive lansoprazole 30 mg or omeprazole 20 mg daily for 4–8 weeks. Daily assessment of symptoms was made by the patient using a 100-mm Visual Analogue Scale. Clinical symptoms were evaluated at weeks 0, 1, 4 and 8. Endoscopic assessment of healing, defined by normalization of the oesophageal mucosal appearance, was made at weeks 4 and 8. Results: Two hundred and eighty-two patients in the lansoprazole group and 283 patients in the omeprazole group were eligible for inclusion in the per protocol analysis. At 3 days, there was a significant improvement in daytime symptoms of heartburn for patients in the lansoprazole group compared with the omeprazole group (P=0.05). A similar but non-significant trend was seen at 7 days (P=0.18). Clinical assessment at 7 days demonstrated significant improvement in daytime epigastric pain in the lansoprazole group compared with the omeprazole group (P=0.03), with a similar but non-significant trend in night-time epigastric pain (P=0.07). Healing rates of oesophagitis at 4 and 8 weeks were 70 and 87%, respectively, with lansoprazole, and 63 and 82%, respectively, with omeprazole. Logistic regression analysis of the cumulative healing rates, which included baseline factors affecting outcome, resulted in an odds ratio of 1.46 (95% CI=0.87–2.45), suggesting a higher chance of being healed with lansoprazole treatment compared with omeprazole treatment. A total of 615 adverse events were reported by 308 (51%) patients during the study period. The majority of events were mild in nature and the incidence was similar in both treatment groups. The most frequently reported events were headache, diarrhoea and nausea. Conclusion: Lansoprazole provides greater symptom relief compared with omeprazole during the first week of treatment. Both treatments were effective in healing oesophagitis. 相似文献
65.
66.
Report of the NASPE Policy Conference Training Requirements for Permanent Pacemaker Selection, Implantation, and Follow-Up 总被引:4,自引:0,他引:4
67.
Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder 总被引:10,自引:0,他引:10
ISAO HARA HIDEAKI MIYAKE YOSHIZUMI TAKECHI HIROSHI ETO AKINOBU GOTOH MASATO FUJISAWA HIROSHI OKADA SOICHI ARAKAWA SADAO KAMIDONO KOBE UROGENITAL TUMOR STUDY GROUP 《International journal of urology》2003,10(1):19-24
BACKGROUND: The objective of this study was to retrospectively investigate the effectiveness of transurethral resection of bladder tumor (TURBT) and intravesical instillation therapy for stage T1, grade 3 (T1G3) transitional cell carcinoma (TCC) of the urinary bladder. METHODS: Between January 1995 and December 1997, 97 patients with T1G3 TCC of the urinary bladder were treated by TURBT and adjuvant intravesical instillation with bacillus Calmette-Guérin (BCG) or other anticancer agents. The recurrence-free survival rates were evaluated according to several clinicopathological factors. The cases that progressed to muscle invasive disease were also analysed. RESULTS: In this series, the median follow-up period was 25 months (range, 5- 41) after the initial TURBT. Intravesical recurrence was noted in 44 patients (45%), and the 1, 2, and 3 year recurrence-free survival rates were 72%, 58%, and 42%, respectively. Multivariate analyses revealed that the risk of intravesical recurrence was significantly higher for patients who did not receive BCG therapy, irrespective of age, gender, tumor size, multiplicity, pathological stage, concomitant carcinoma in situ, and lymphovascular involvement. Moreover, after a median of 10 months, disease progression occurred in seven patients (7%), of which only one patient was treated by BCG therapy after initial TURBT. CONCLUSION: These findings suggest that intravesical instillation with BCG combined with TURBT is an effective conservative treatment for T1G3 TCC of the bladder. Patients with negative prognostic factors should be treated by BCG rather than other anticancer agents after TURBT. 相似文献
68.
MADSEN J. KOERSTZ; HANSEN J. FISCHER; THE DAVIT-II STUDY GROUP 《European heart journal》1993,14(3):377-379
The 18 month mortality rate in 2180 patients excluded from theDanish Verapamil Infarction Trial II (DAVIT II) was 25.6%. Innon-consenters (n = 368) this was 15.0% compared with 13.8%in 897 placebo-treated patients (hazard ratio 1.09 [P = 0.60]when adjusting for sex and age). The increased mortality ratein excluded patients is attributed to heart failure (45.8% andother severe diseases (38.9%). 相似文献
69.
Lee SS Bain VG Peltekian K Krajden M Yoshida EM Deschenes M Heathcote J Bailey RJ Simonyi S Sherman M;CANADIAN PEGASYS STUDY GROUP 《Alimentary pharmacology & therapeutics》2006,23(3):397-408
BACKGROUND: Pegylated interferon alfa-2a (40 KD) plus ribavirin therapy induces sustained virological response rates up to 63% in randomized-controlled trials. AIM: To conduct a prospective open-label programme to examine the efficacy and safety of this therapy in routine clinical practice. Methods: Treatment-naive patients with chronic hepatitis C received, at the discretion of the investigator, pegylated interferon alfa-2a 180 microg/week + ribavirin 800 mg/day for 24 or 48 weeks. In total, 508 patients were enrolled [334 non-cirrhotic; 174 cirrhotic (defined as stage F3 and F4)]. RESULTS: In genotype 1 patients treated for 48 weeks, sustained virological response rates were 41% in non-cirrhotics and 34% in cirrhotics. Sustained virological response rates in genotype 2 or 3 non-cirrhotics were 79% (24 weeks) and 72% (48 weeks). Corresponding values for cirrhotic genotype 2/3 were 66% and 44%. The negative predictive value of an early virological response at week 12 was 94%. Predictive factors for sustained virological response on multivariate analysis were genotype (2/3 vs. 1), low viral load and degree of fibrosis. Rates of serious adverse events (相似文献
70.
CO-OPERATIVE CLINICAL STUDY GROUP FOR ESOPHAGEAL CARCINOMA 《Japanese journal of clinical oncology》1980,10(2):215-220
A cooperative study was conducted to examine the effect of bleomycin(BLM) or FT-207 which was combined with preoperative radiotherapy.To both groups of patients a solid form of BLM was administeredduring surgery and FT-207 after surgery. From July 1978 to June1980, 267 cases of esophageal carcinoma were treated accordingto this protocol. Resective surgery was performed on 199 patients,and in 171 of these, six months had passed after the operation.These 171 cases were studied. There were 79 patients in theBLM group and 92 in the FT-207 group. There was no disparityin fluoroscopic findings, age distribution or sex ratio. TheBLM group had a slightly higher operative mortality. There wasno significant difference in survival or in histological effectin the resected specimen. A total dose of 12,500 mg of suppositoryFT-207 had the same effect as a total dose of 45 mg of BLM.FT-207 is easier to administer to patients with esophageal carcinoma.
The members of this group are: Toshifumi lizuka, M.D. (NationalCancer Center Hospital, Mitsuo Endo, M.D. (Tokyo Women's MedicalCollege), Koichi Sasaki, M.D. (Niigata University), Kazuo Karasawa,M.D. (Aichi Cancer Center Hospital), Teruo Kakegawa, M.D. (KeioUniversity), Masaki Arimori, M.D. (The 2nd Tokyo National Hospital)and Tetsuji Sasaki, M.D. (Nagoya Hoken Eisei University). 相似文献